Mission
PROVIDING ANTI-RETROVIRALS TO ELIGIBLE HIV VACCINE TRIALS NETWORK PARTICIPANTS.
Public Charity
Seattle Vaccine Research Fund
Based in SEATTLE, WA, Seattle Vaccine Research Fund operates as a Public Charity. The organization reported $122K in revenue, $2.9M in total assets for fiscal year 2025.
EIN: 331111221
SEATTLE, WA
Single Organization Support
NTEE: G11
Latest filing: 2025
Total Revenue$122K
Total Assets$2.9M
Grant Records0
Filing Years2022–2025
Where $100 goes at Seattle Vaccine Research Fund
How Seattle Vaccine Research Fund divides every $100 it spends, from its own Form 990 filings, averaged across 4 years.
$100
Programs
the work itself
<$1
Management
running the organization
$0
Fundraising
none reported
No fundraising costs are reported. That often means fundraising runs through a separate affiliated organization that files its own return.
Inside the $100 for programs
$100
Providing anti-retrovirals to eligible HIV vaccine trials network participants
Source: Form 990 filings with the IRS, latest fiscal year 2025. Shares are from the organization's reported expenses. Data by Imperigo; not affiliated with the IRS.
Officers & Directors
Secretary and Treasurer
Bryon Epp
Director
Cindy Zehnder
Vice-President
James Kublin Md Mph
President
Lawrence Corey Md
Director
Scott Wilson
Officer compensation and complete director data available with membership.
Financial Trends
| Year | Revenue | Expenses | Assets |
|---|---|---|---|
| 2025 | $122K | — | $2.9M |
| 2024 | $131K | — | $2.8M |
| 2023 | $89K | $3K | $2.6M |
| 2022 | $6K | $225K | $2.5M |
Between 2022 and 2025, reported annual revenue grew from $6K to $122K (+2120%), with total assets most recently reported at $2.9M.
Interactive year-over-year charts and full filing details available with membership.